U.S. Patent and Trademark Office Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10693792			
iling Date		2003-10-24			
irst Named Inventor Gesot		tti			
Art Unit		3762			
Examiner Name	Michael William Kahelin				
Marray Dealest Number		105 0071 1004			

					U.S.	PATENTS			Remove		
		Kind Code ¹			Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1										
If you wis	h to a	l dadditional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion				nt Passaç	Lines where ges or Relev	
	1										
If you wisl	h to a	dd additional U.S. Publi				,		d button	=		
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document Pages, Colun where Relevi Passages or Figures Appe		evant or Relevant	т.	
	1										
If you wis	h to a	l dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	button	Add		
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Cite Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or occurity where published.								Τs			

| Application Number | 1069/3792 | Fing Date | 2003-10-24 | Fing Date |

	1	HLDIOK-SMITH, M., "Pragmatic physical therapy in Parkmoon's disease: Any scientific base?", in Stem CM (ed) "Parkmoon's Blease Advances in Neurology", 1999, Page(s) 561-564, Volume 90, Publisher: Lippincott Williams and Wilkins, Published in: Philadelphia. US	
	2	IANSEK, ROBERT, "Intensisciplinsny Rehabilition in Parkinson's Disease", in Stem GM (ed): "Parkinson's Disease. Advances in Neurology", 1999, Page(s) 561-564, Yotune 80, Publisher: Lippincott Williams and Wilkins, Published in: Philodophin, US	

If you wish to add additional non-patent literature document citation information please click the Add button Add

FXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTD Patent Documents at <u>wine USPTD GDV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPD Standard ST-3). ² For Japanese parter documents, by a soliculation of the year of the entgr of the Empire transpressed his serial number of the platent document. Will be a soliculated to the Standard ST-3 of the place transpress to the place at color such that the first color of the standard ST-3 of the place at color such that the first color of the standard ST-3 of the place at color such that the first color of the standard ST-3 of the

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10693792		
Filing Date		2003-10-24		
First Named Inventor	Gesotti			
Art Unit		3762		
Examiner Name	Michael William Kahelin			
Attaces Desirat Number		405 0071 1004		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to ma	ke the appropri	iate selection(s):
---------------	----------	----------------	-----------------	--------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/David N. Fogg/	Date (YYYY-MM-DD)	2007-03-06
Name/Print	Fogg, David N.	Registration Number	35138

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.